The effect of remimazolam on the incidence of nausea and vomiting after general anesthesia in high-risk patients: a prospective randomized controlled study

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100043060

Enrollment

Unknown

Registered

2021-02-04

Start date

2021-01-31

Completion date

Unknown

Last updated

2021-05-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Nausea and Vomiting

Interventions

trial group:Remimazolam

control group:Placebo

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1) Aged >=18 years; 2) Patients who intend to undergo elective surgery under general anesthesia; 3) Patients at high risk of postoperative nausea and vomiting. Using the Apfel concise risk factor score, patients with the following 3 or more factors are considered high-risk patients: women, non-smokers, history of PONV, postoperative use of opioids.

Exclusion criteria

Exclusion criteria: 1) Decline to participate; 2) History of schizophrenia, epilepsy, Parkinson's disease or myasthenia gravis; 3) Severe liver dysfunction (Child-Pugh class C); 4) Severe renal dysfunction (dialysis required); 5) ASA grade 4 and above; 6) Emergency surgery; 7) Taking benzodiazepines continuously for more than 1 week before surgery.

Design outcomes

Primary

Measure	Time frame
24h PONV;	—

Secondary

Measure	Time frame
48h PONV;Emergence Delirium;Delirium in POD3;Postoperaive hospital stay;Morbidity in 30 days;awareness;Sleep Quality in POD3;Pain score POD1-3;Dream rate;	—

Countries

China

Contacts

Public ContactDongxin Wang

Peking University First Hospital

wangdongxin@hotmail.com+86 13910731903

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026